If You Invested in Hemostemix (HMTXF)

Hemostemix Inc. (HMTXF) is an autologous stem cell therapy platform company in the field of biotechnology research and development. According to the company, it focuses on blood-based, patient-derived cell therapies for ischemic conditions that cause pain, tissue damage, and loss of function. Hemostemix trades on the OTCQB under the symbol HMTXF and on the TSX Venture Exchange under the symbol HEM, and operates within the professional, scientific, and technical services sector.

Founded in 2003, Hemostemix describes itself as an autologous stem cell therapy platform company that has developed, patented, and is scaling and selling its blood-based stem cell therapy known as VesCell™ (ACP-01). The company characterizes VesCell (ACP-01) as an autologous angiogenic cell therapy platform derived from the patient’s own blood. Hemostemix reports that it has completed seven clinical studies involving 318 subjects and has published results in eleven peer-reviewed publications.

Core therapy focus: ACP-01 (VesCell)

Hemostemix identifies its primary therapeutic platform as ACP-01 (Angiogenic Cell Precursors), a blood-based autologous stem cell therapy. The company states that ACP-01 is designed to address ischemia-driven disease by promoting angiogenesis and microvascular repair. Based on company disclosures, ACP-01 is positioned as a treatment for multiple ischemic indications, including:

• Peripheral arterial disease (PAD)
• Chronic limb threatening ischemia (CLTI)
• Angina
• Ischemic cardiomyopathy
• Non-ischemic dilated cardiomyopathy
• Congestive heart failure
• Total body ischemia
• Vascular dementia

Hemostemix reports that ACP-01 has been found to be safe, clinically relevant, and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. The company notes that it completed a Phase II clinical trial for chronic limb threatening ischemia and published the results in the Journal of Biomedical Research & Environmental Science.

Clinical evidence and peer-reviewed publications

Across multiple news releases, Hemostemix emphasizes its clinical data set. The company states that it has:

• Completed seven clinical studies involving 318 subjects.
• Published results in eleven peer-reviewed publications.
• Generated data in chronic limb threatening ischemia showing wound healing, pain reduction, and limb preservation outcomes.

Hemostemix highlights a comparison for CLTI patients, noting that, as compared to a five-year mortality rate of 50% in the CLTI patient population, results reported by collaborators at the University of British Columbia and the University of Toronto to a meeting of vascular surgeons showed 0% mortality, cessation of pain, and wound healing in 83% of patients followed for up to 4.5 years as a midpoint result. The company also references published analyses where ulcer size in treated patients decreased markedly over three months, with lower rates of amputation and death in the treatment group compared with placebo.

Regenerative medicine and ischemia-based strategy

Hemostemix positions itself as a regenerative medicine company focused on ischemic disease. In its disclosures, the company describes ACP-01 as an autologous, blood-derived therapy aimed at regenerating microvascular circulation, improving perfusion, and reducing ischemic pain. Hemostemix links these mechanisms to improved exercise capacity, accelerated wound healing, restored mobility, and enhanced quality of life for patients with severe ischemic peripheral arterial disease and related conditions.

The company also refers to an ischemia-based clinical strategy that groups multiple conditions under a single mechanism of action for ACP-01. In connection with a planned basket protocol, Hemostemix notes that ischemic conditions such as vascular dementia, ischemic cardiomyopathy, peripheral arterial disease, and generalized ischemia may be addressed within a unified trial framework.

Commercialization and clinical operations

Hemostemix describes itself as scaling and selling VesCell (ACP-01) and references commercialization initiatives in several jurisdictions. In company communications, Hemostemix states that it is:

• Commercializing VesCell (ACP-01) as a treatment for conditions of ischemia.
• Advancing regulatory, clinical, and commercialization initiatives related to ACP-01.
• Building clinical operations and patient-care infrastructure in locations such as Florida, The Bahamas, Canada, and the Dominican Republic, subject to applicable regulatory pathways.

The company notes that ACP-01 is available to certain patients under specific frameworks, including references to Florida SB 1768 for compassionate treatments, and mentions treatment activity at Doctors Hospital in Nassau, The Bahamas. It also describes a clinic roll-up and commercialization strategy that includes acquiring cardiology practices where ACP-01 can be integrated into existing cardiovascular care, with the goal of generating a predictable stream of patients for treatment with ACP-01.

Regulatory and clinical development pathway

Hemostemix reports that it is pursuing regulatory engagement for ACP-01. The company has announced that the U.S. Food and Drug Administration scheduled a Pre-IND meeting to review its basket clinical trial protocol for ischemia-related indications, including vascular dementia, ischemic cardiomyopathy, peripheral arterial disease, and generalized ischemia. The company indicates that this basket protocol is intended to support a Phase I clinical trial of ACP-01.

For vascular dementia, Hemostemix has disclosed that ACP-01 is an investigational autologous cell therapy and is not approved by the U.S. FDA or Health Canada for this indication. The company notes that a Phase I vascular dementia protocol has been submitted to an Institutional Review Board, revised following initial comments, and resubmitted for final IRB approval. The planned study is described as focusing on safety, feasibility, and potential cognitive benefits in patients with vascular contributions to cognitive impairment.

Corporate recognition and awards

Hemostemix states that it is a winner of the World Economic Forum Technology Pioneer Award. This recognition is cited by the company in connection with its development of autologous blood-based stem cell therapy and its positioning within regenerative medicine.

Financing and capital markets activity

Company news releases describe Hemostemix’s use of equity financing to fund operations. Examples include non-brokered private placements of common shares and units, subject to TSX Venture Exchange approval, with proceeds earmarked for working capital, regulatory preparations, clinical operations, and commercialization activities related to ACP-01. The company also reports the grant of stock options to directors, officers, employees, and consultants under its stock option plan.

Events, partnerships, and clinical collaborations

Hemostemix highlights participation in medical conferences and collaborations with clinicians as part of its strategy. The company reports:

• Participation as a regenerative medicine company at Innovations in Wound Healing 2025, where it presented clinical evidence in chronic limb threatening ischemia and related cardiovascular conditions.
• Attendance at DFCon 2025, a conference focused on diabetic foot care and limb preservation, to discuss outcomes following ACP-01 treatment for vascular and ischemic conditions underlying chronic wounds and diabetic limb-threatening ischemia.
• Engagement of experienced clinicians and advisors, including podiatrists, cardiologists, and neurologists, to support physician education, clinical implementation of ACP-01, and trial leadership for specific indications such as vascular dementia.

Business model characteristics

Based on the company’s disclosures, Hemostemix’s activities combine biotechnology research and development with clinical and commercialization initiatives. The company’s model centers on:

• Developing and patenting autologous stem cell therapies derived from patient blood.
• Conducting clinical studies and publishing peer-reviewed data on ACP-01.
• Pursuing regulatory pathways for ACP-01 in ischemic indications.
• Scaling and selling VesCell (ACP-01) within regulatory frameworks that permit treatment, including compassionate or jurisdiction-specific pathways.
• Building or acquiring clinical infrastructure, such as cardiology practices and treatment programs, to support patient access and data collection.

Risk and forward-looking considerations

Hemostemix’s news releases include extensive forward-looking information disclaimers. The company notes that outcomes related to clinical trials, regulatory approvals, commercialization of ACP-01, financing, and market acceptance are subject to risks and uncertainties. It identifies factors such as the ability to complete clinical trials, obtain regulatory approvals, secure financing, manage litigation, and respond to economic and healthcare sector conditions as potential influences on its performance.

Frequently asked questions (FAQ)